SEC Form 4 · accession 0001209191-18-014341
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Feb 26, 2018
Accepted (ET)
Feb 28, 2018 · 9:30 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 26, 2018 | M | 2,155 | $91.05 | A | 48,817 | D | |
| Common Stock | Feb 26, 2018 | S | 2,155 | $170.00 | D | 46,662 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) | |
| Common Stock | holding | — | — | — | 12,215 | I | Held in Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | Feb 26, 2018 | M | 2,155 | D | — | Feb 1, 2026 | Common Stock | 2,155 | 17,242 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 2/2/2016.